Biologicals for the treatment of systemic lupus erythematosus?

References

• Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, . Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007;27:461–6.
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, . Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000;43:1790–800.
   PubMed Web of Science ®Google Scholar
• Jacob CO, McDevitt HO. Tumour necrosis factor-a in murine autoimmune ‘lupus’ nephritis. Nature. 1988;331: 356–8.
   PubMed Web of Science ®Google Scholar
• Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, . Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis. 2004;63:1075–8.
   PubMed Web of Science ®Google Scholar
• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50:3161–9.
   PubMed Web of Science ®Google Scholar
• Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, . Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009;48:1451–4.
   PubMed Web of Science ®Google Scholar
• Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, . Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9:664–71.
   PubMed Web of Science ®Google Scholar
• Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, . Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785–96.
   PubMed Web of Science ®Google Scholar
• McBride JM, Wallace D, Yao Z, Morimoto A, Jiang J, Maciuca R, . Dose-dependent modulation of Interferon regulated genes with in administration of single and repeat doses of rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE (abstract 2072). Arthritis Rheum. 2009;60(Suppl):S775–6.
   Google Scholar
• Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18:565–70.
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, . Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542–52.
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, . B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–9.
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44:1542–5.
   PubMed Web of Science ®Google Scholar
• Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56:1263–72.
   PubMed Web of Science ®Google Scholar
• Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67:330–4.
   PubMed Web of Science ®Google Scholar
• Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35:826–33.
   PubMed Web of Science ®Google Scholar
• Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, . A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009;61:482–7.
   PubMed Web of Science ®Google Scholar
• Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25:3586–92.
   PubMed Web of Science ®Google Scholar
• Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, . Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62:2458–66.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.
   PubMed Web of Science ®Google Scholar
• Furie RA, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, . Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized double-blind phase III LUNAR study. Arthritis Rheum. 2009;60(Suppl 1):S429.
   Google Scholar
• Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis. 2008;67(Suppl III):64–5.
   Google Scholar
• Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74.
   PubMed Web of Science ®Google Scholar
• Wallace D, Kalunian K, Petri M, Strand V, Killgallen B, Barry A, . Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIB study. Ann Rheum Dis. 2010;69(Suppl3):558.
   Google Scholar
• Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, . A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–78.
   PubMed Web of Science ®Google Scholar
• Chatham W, Weinstein A, Petri M, Merrill JT, Furie R, Wallace D, . Five-year safety and efficacy experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis. 2010; 69(Suppl3):147.
   Google Scholar
• Navarra S, Ilianova E, Bae S, Guzman R, Tanasescu C, Gallacher A, . Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis. 2010;69(Suppl3):555.
   Google Scholar
• Looney J. B cell-targeted therapies for systemic lupus erythematosus. Drugs. 2010;70:529–40.
   PubMed Web of Science ®Google Scholar
• Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, . Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142–50.
   PubMed Web of Science ®Google Scholar
• Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol. 1997;24:314–8.
   PubMed Web of Science ®Google Scholar
• Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008;58:2470–80.
   PubMed Web of Science ®Google Scholar
• Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol. 1996;157:3159–64.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:3251–8.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, . A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719–27.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, . The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: Results of A 12-month exploratory study. Arthritis Rheum. 2010;62:3077–87.
   PubMed Web of Science ®Google Scholar